
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington -- New therapies continue to emerge in pediatric dermatology, and recent studies demonstrate the effectiveness of such therapies. Ilona J. Frieden, M.D., highlighted studies in some areas of common concern in a presentation at the annual meeting of the American Academy of Dermatology.






